back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2020-12-18 18:42 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Shou, Yaping
5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
90 - Change in the nature of ownership
|
+275,833 vol |
275,833 | |
| Filed 2020-12-18 18:40 Tx date 2018-06-11 |
$TRIL
Trillium Therapeutics Inc. |
Shou, Yaping
5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-12-18 18:12 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Shou, Yaping
5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-275,833 vol |
379,167 | |
| Filed 2019-11-12 10:43 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Shou, Yaping
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$89,300
+235,000 vol $0.38 each |
655,000 | |
| Filed 2019-05-27 12:42 Tx date 2019-05-10 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Shou, Yaping
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$115,500
+150,000 vol $0.77 each |
420,000 | |
| Filed 2018-11-13 Tx date 2018-06-11 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Shou, Yaping
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-11-13 Tx date 2018-07-03 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Shou, Yaping
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,580,000
+200,000 vol $7.90 each |
200,000 | |
| Filed 2018-11-13 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Shou, Yaping
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$296,100
+70,000 vol $4.23 each |
270,000 |